Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International Feb 6, 2020 08:11AM
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International Feb 6, 2020 08:11AM
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori Jan 30, 2020 09:05AM
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products Jan 2, 2020 08:14AM
Amarantus to Present at 12th Annual LD Micro Main Event Dec 9, 2019 08:00AM
View Older Stories

Dec 4, 2019 07:36AM Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
Nov 21, 2019 08:00AM Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
Nov 18, 2019 08:30AM Amarantus Provides Recapitalization Update to Shareholders
Oct 24, 2019 09:34AM Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
Jun 25, 2019 08:00AM Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking
Jun 18, 2019 08:00AM Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Jun 13, 2019 08:42AM Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
Jun 4, 2019 01:39PM Amarantus to Present at 9th Annual LD Micro Invitational Conference
May 31, 2019 11:01AM Amarantus Releases Letter to Shareholders
May 28, 2019 09:30AM Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry
May 28, 2019 08:57AM Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
Feb 28, 2019 09:30AM Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Jan 17, 2019 07:00AM MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
Jan 15, 2019 07:00AM MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa
Jan 11, 2019 05:00AM Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
Jan 7, 2019 08:00AM Amarantus Provides 2019 Roadmap
Dec 3, 2018 08:30AM Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Nov 28, 2018 07:55AM Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
Jul 20, 2018 08:17AM Amarantus Provides Corporate Update
Jun 7, 2018 09:08AM Amarantus Provides Update on Elto Pharma Capital Formation Plan
Jun 5, 2018 08:11AM MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances
May 30, 2018 08:00AM Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
May 24, 2018 11:00AM Amarantus to Present at LD Micro and The Reg A Conference
May 22, 2018 06:00AM Amarantus Retains Weild & Co. to Advise on JOBS Act Funding
May 11, 2018 10:25AM Amarantus Provides Business Overview
May 4, 2018 08:45AM Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
May 3, 2018 09:15AM MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's
May 1, 2018 10:31AM Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment
Apr 30, 2018 07:00AM Elto PharmaAppoints Paula Trzepacz, MD asChief Medical Advisor
Apr 16, 2018 07:31AM Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program
Apr 9, 2018 01:10PM Amarantus to Present at The Microcap Conference in NYC
Apr 6, 2018 11:24AM Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test
Apr 5, 2018 08:00AM Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor
Apr 2, 2018 09:49AM Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City
Mar 28, 2018 01:41PM Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City
Mar 8, 2018 08:00AM Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia
Mar 5, 2018 08:00AM Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
Mar 1, 2018 06:00AM MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231
Feb 26, 2018 05:56PM Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
Jan 29, 2018 09:00AM Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease
Jan 23, 2018 09:59AM Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
Jan 9, 2018 10:59AM Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018
Jan 4, 2018 09:45AM Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
Jan 3, 2018 08:00AM Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Bio
Dec 26, 2017 07:30AM Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
Dec 20, 2017 09:02AM Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
Dec 14, 2017 08:00AM Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF a
Dec 11, 2017 08:00AM Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
Dec 8, 2017 10:27AM Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
Dec 5, 2017 07:45AM Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson&ap
View Older Stories